Reports Q2 revenue $39.56M, consensus $39.13M. David Bailey, president and CEO of OrthoPediatrics, commented, “I am pleased with our execution across the business in the second quarter. Strong commercial and operational performances drove robust revenue growth and improved operating leverage as we observed gradual month-by-month improvements within the children’s hospitals inpatient surgical environment. Looking ahead, we are favorably positioned for the second half of the year as new product development and launches, set consignments, 7D system placements and prolific surgeon training and education, support adoption and further share gains for OrthoPediatrics.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results
- Is KIDS a Buy, Before Earnings?
- OrthoPediatrics Corp. to Report Second Quarter 2023 Financial Results on August 1, 2023
- OrthoPediatrics launches, first case using GIRO Growth Modulation System
- OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO™ Growth Modulation System